Hvis der forekommer tegn eller symptomer på depression under behandling med sibutramin, bør behandlingen med sibutramin seponeres og anden passende behandling bør overvejes.
In the European Union (EU) it was approved in Germany in January 1999 and subsequently applications were submitted in all Member States, except France, through the Mutual Recognition Procedure (MRP).